CL2014000449A1 - Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos. - Google Patents

Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos.

Info

Publication number
CL2014000449A1
CL2014000449A1 CL2014000449A CL2014000449A CL2014000449A1 CL 2014000449 A1 CL2014000449 A1 CL 2014000449A1 CL 2014000449 A CL2014000449 A CL 2014000449A CL 2014000449 A CL2014000449 A CL 2014000449A CL 2014000449 A1 CL2014000449 A1 CL 2014000449A1
Authority
CL
Chile
Prior art keywords
iap
shps
igf
monoclonal antibody
therapeutic uses
Prior art date
Application number
CL2014000449A
Other languages
English (en)
Inventor
David R Clemmons
Laura A Maile
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of CL2014000449A1 publication Critical patent/CL2014000449A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000449A 2011-08-26 2014-02-25 Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos. CL2014000449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/219,276 US8613922B2 (en) 2003-04-24 2011-08-26 Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)

Publications (1)

Publication Number Publication Date
CL2014000449A1 true CL2014000449A1 (es) 2015-01-16

Family

ID=47756771

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000449A CL2014000449A1 (es) 2011-08-26 2014-02-25 Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos.

Country Status (15)

Country Link
US (4) US8613922B2 (es)
EP (1) EP2747784A4 (es)
JP (1) JP6277127B2 (es)
KR (1) KR20140090975A (es)
CN (1) CN104053452B (es)
AU (1) AU2012300314A1 (es)
BR (1) BR112014004385A2 (es)
CA (1) CA2846248A1 (es)
CL (1) CL2014000449A1 (es)
HK (1) HK1199212A1 (es)
IL (1) IL231162A0 (es)
MX (1) MX2014002296A (es)
RU (1) RU2014111472A (es)
WO (1) WO2013032948A1 (es)
ZA (1) ZA201401450B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
EP2968536B1 (en) * 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
ES2822561T3 (es) * 2014-09-15 2021-05-04 Univ Leland Stanford Junior Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis
ES2941387T3 (es) 2015-02-27 2023-05-22 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
US10973867B2 (en) * 2015-12-30 2021-04-13 Marshall University Research Corporation Compositions and methods for treating retinopathy
MX2018012434A (es) * 2016-04-14 2019-06-06 Ose Immunotherapeutics Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas.
WO2017178653A2 (en) * 2016-04-14 2017-10-19 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
SG11202000658PA (en) 2017-07-26 2020-02-27 Forty Seven Inc Anti-sirp-alpha antibodies and related methods
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
EP3717515A2 (en) 2017-12-01 2020-10-07 Seattle Genetics, Inc. Cd47 (masked) antibodies and uses thereof for treating cancer
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法
KR20200133376A (ko) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. 신호-조절 단백질 알파에 대한 항체 및 사용 방법
CN112673023B (zh) * 2018-07-10 2023-09-12 国立大学法人神户大学 抗SIRPα抗体
EP3823981A4 (en) * 2018-07-17 2022-04-06 Neuromyon Inc. TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
WO2020243338A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
US20230136228A1 (en) 2019-09-18 2023-05-04 Lamkap Bio Alpha AG Bispecific antibodies against ceacam5 and cd3
WO2022254379A1 (en) 2021-06-04 2022-12-08 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432611A (en) 1977-08-16 1979-03-10 Nobuhiko Katsunuma Glucocorticoid saving factor
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859765A (en) 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5874231A (en) 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
AU2232597A (en) 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
PL339265A1 (en) 1997-09-11 2000-12-04 Chugai Pharmaceutical Co Ltd Apoptose causing monoclonal antibody
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
US6753146B1 (en) 1999-02-23 2004-06-22 Eric F. Bernstein System and method for evaluating agents which prevent oxidative damage
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
US7261892B2 (en) * 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en) * 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
KR20060121150A (ko) 2003-11-11 2006-11-28 추가이 세이야쿠 가부시키가이샤 인간화 항-ｃｄ47 항체
EP2629478B1 (en) 2012-02-16 2018-05-16 BlackBerry Limited Method and apparatus for separation of connection data by perimeter type

Also Published As

Publication number Publication date
NZ621515A (en) 2016-03-31
US9475882B2 (en) 2016-10-25
EP2747784A1 (en) 2014-07-02
CA2846248A1 (en) 2013-03-07
US20170114134A1 (en) 2017-04-27
JP6277127B2 (ja) 2018-02-07
US20120039896A1 (en) 2012-02-16
US8613922B2 (en) 2013-12-24
RU2014111472A (ru) 2015-11-27
MX2014002296A (es) 2014-03-27
HK1199212A1 (en) 2015-06-26
AU2012300314A1 (en) 2014-03-13
KR20140090975A (ko) 2014-07-18
US20140141002A1 (en) 2014-05-22
IL231162A0 (en) 2014-04-30
CN104053452A (zh) 2014-09-17
CN104053452B (zh) 2016-11-09
WO2013032948A1 (en) 2013-03-07
ZA201401450B (en) 2014-11-26
US20160297866A1 (en) 2016-10-13
EP2747784A4 (en) 2015-05-06
JP2014525940A (ja) 2014-10-02
BR112014004385A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
CL2014000449A1 (es) Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos.
HK1252895A1 (zh) 識別α-突觸核蛋白的人源化抗體
HK1223943A1 (zh) 嵌合的靶向抗原受體的單克隆抗體
ZA201400768B (en) Interleukin-31 monoclonal antibody
BR112013032552A2 (pt) variantes de anticorpos monoclonais humanizados imunomoduladores
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
DK2825559T3 (da) Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
EP3029069A4 (en) Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
HK1199038A1 (en) Anti-human xcr1 antibodies xcr1
IL240008A0 (en) A humanized antibody against hmgb1 or an antigen-binding fragment thereof
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
HK1212896A1 (zh) 針對活化蛋白 的單克隆抗體
HK1215174A1 (zh) 針對活化蛋白 的人源化單克隆抗體及其用途
HK1175486A1 (zh) 抗腫瘤壞死因子α的人源化抗體